ClinicalTrials.gg
CompletedNCT01454115Updated Nov 21, 2011

Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

A Phase 1 interventional study of BMS-708163 (Gamma-Secretase Inhibitor) and BMS-708163 (Gamma-Secretase Inhibitor) in Alzheimer's Disease, sponsored by Bristol-Myers Squibb. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-21.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing BMS 708163 in Alzheimer Disease — none open to participants now, none under way, none of them phase 3. BMS 708163 · Alzheimer Disease.

Enrollment
3rd of 12
116 · median 31
Started
2007
the only one that year
Phase 1
10 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
12 of 12
Bristol-Myers Squibb

Among the 12 studies testing BMS 708163 in Alzheimer Disease, this one is the 3rd largest by enrollment, is the only one that started in 2007, is one of 10 in phase 1, and was the 12th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

None of the 12 studies testing BMS 708163 in Alzheimer Disease is open now. The open studies under Alzheimer Disease, anywhere →

About BMS 708163

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing BMS 708163 in Alzheimer Disease as a file.
02

Study summary

The primary objective is to assess the safety and tolerability of a single oral dose of BMS-708163 in healthy young male subjects and in elderly male and female subjects.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Panels 1- 8 and Panels 14-15: healthy male subjects between the ages of 18 to 45
  • Panels 9 and 10: healthy elderly males and females ages 60 and greater
  • Panel 11: healthy males between the ages of 46-59
  • Panel 12: males and/or females either healthy or with mild cognitive impairment (MCI) between the ages of 60 and 74
  • Panel 13: males and/or females, healthy or with Alzheimer's disease (AD) or MCI that were 75 years of age or greater
  • Acceptable medical history, physical examinations, vital signs, , hemoccult stool tests, and clinical laboratory evaluations
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Panel 1: BMS-708163 or Placebo

    Healthy male subjects (age: 18 to 45 years)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 2: BMS-708163 or Placebo

    Healthy male subjects (age: 18 to 45 years)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 3: BMS-708163 or Placebo

    Healthy male subjects (age: 18 to 45 years)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 4: BMS-708163 or Placebo

    Healthy male subjects (age: 18 to 45 years)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 5: BMS-708163 or Placebo

    Healthy male subjects (age: 18 to 45 years). In Period 2: Subjects will receive BMS-708163 or placebo as a capsule formulation. In Period 3: Subjects will receive BMS-708163 or placebo as a capsule formulation within 5 minutes of consuming a standard high-fat breakfast on Day 1

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 6: BMS-708163 or Placebo

    Healthy male subjects (age: 18 to 45 years)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 7: BMS-708163 or Placebo

    Healthy male subjects (age: 18 to 45 years)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 8: BMS-708163 or Placebo

    Healthy male subjects (age: 18 to 45 years)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 9: BMS-708163 or Placebo

    Healthy, elderly male subjects (age: 60 years and greater)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 10: BMS-708163 or Placebo

    Healthy, elderly female subjects (age: 60 years and greater)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 11: BMS-708163 or Placebo

    Healthy male subjects (age: between 46 to 59 years)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 12: BMS-708163 or Placebo

    Healthy male and/or female subjects or subjects with MCI (age: between 60-74 years)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 13: BMS-708163 or Placebo

    Healthy male and/or female subjects or with AD or MCI (age: 75 years or greater)

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

  • Experimental
    Panel 15: BMS-708163 or Placebo

    Healthy young male subjects

    Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of Single doses of BMS-708163 in the range of 0.3 to 800 mg in the healthy subjects

    Based on adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests

    Time frame: Within 28 days of dosing

Secondary outcomes

  1. Effects of BMS-708163 on cortisol and QT interval corrected for heart rate

    Time frame: Within 28 days of dosing

  2. Effect of BMS-708163 on thyroid stimulating hormone (TSH), free triiodothyronine (T3), free thyroxine (T4), and lymphocyte subsets

    Time frame: Within 28 days of dosing

  3. Bioavailability of BMS-708163 from a capsule formulation relative to a solution formulation

    Time frame: Within 28 days of dosing

  4. Effect of food on the PK of BMS-708163 administered as a capsule formulation

    Time frame: Within 28 days of dosing

  5. Maximum observed plasma concentration (Cmax) of BMS-708163

    Time frame: Within 28 days of dosing

  6. Time of maximum observed plasma concentration (Tmax) of BMS-708163

    Time frame: Within 28 days of dosing

  7. Area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-708163

    Time frame: Within 28 days of dosing

  8. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-708163

    Time frame: Within 28 days of dosing

  9. Plasma half-life (T-HALF) of BMS-708163

    Time frame: Within 28 days of dosing

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R, Castaneda L, Gu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Dockens RC. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral gamma-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin Ther. 2012 Mar;34(3):654-67. doi: 10.1016/j.clinthera.2012.01.022. Epub 2012 Feb 28. PubMed 22381714 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2011
First posted
Oct 18, 2011
Start
Jun 2007
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Last update
Nov 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01454115
Responsible party
Sponsor
First posted
Oct 18, 2011
Start date
Jun 2007
Primary completion
Mar 2009
Completion
Mar 2009
Last update
Nov 21, 2011

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMS 708163

Start the discussion